trial · primary record
Arikayce
Mycobacterium; Xenopi
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 190 |
| Primary completion | 2030-12 |
| Primary endpoint | variation of sputum conversion rate in ARIKAYCE® addition group compared to standard treatment |
| Registry ID | NCT06585020 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:10.152Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06585020
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.